Position in JNJ
as of Jun 30, 2026
· filed Aug 4, 2026
Position Value
$1,921,029
-$61,868 QoQ
Shares Held
7,564
-6.8% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.30%
of 13F equity value
Holder Rank
#2,387
of 4,664 holders
Holding Since
Mar 2024
10 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in JNJ Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Cascade Financial Partners, LLC holds $290,422,086 across 8 Drug Manufacturers - General names. JNJ ranks #2 (0.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
236,707 | $283,913,500 | |
| 2 | JNJ |
Johnson & Johnson
This page
|
7,564 | $1,921,029 | |
| 3 | MRK |
Merck & Co., Inc.
|
14,746 | $1,894,861 | |
| 4 | NVS |
Novartis AG
|
4,733 | $741,755 | |
| 5 | PFE |
Pfizer Inc
|
26,601 | $640,552 | |
| 6 | ABBV |
AbbVie Inc.
|
2,524 | $635,139 | |
| 7 | AMGN |
Amgen Inc
|
1,284 | $464,962 | |
| 8 | AZN |
Astrazeneca PLC
|
1,109 | $210,288 |
All Filings in JNJ
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,921,029 | 7,564 | Shares | Sole | 2026-08-04 | |
| 2026-03-31 | $1,982,897 | 8,112 | Shares | Sole | 2026-05-12 | |
| 2025-12-31 | $1,712,718 | 8,276 | Shares | Sole | 2026-02-06 | |
| 2025-09-30 | $1,462,778 | 7,889 | Shares | Sole | 2025-10-21 | |
| 2025-06-30 | $1,305,707 | 8,548 | Shares | Sole | 2025-08-07 | |
| 2025-03-31 | $1,405,328 | 8,474 | Shares | Sole | 2025-05-13 | |
| 2024-12-31 | $1,227,823 | 8,490 | Shares | Sole | 2025-02-07 | |
| 2024-09-30 | $1,379,778 | 8,514 | Shares | Sole | 2024-10-25 | |
| 2024-06-30 | $1,206,112 | 8,252 | Shares | Sole | 2024-07-31 | |
| 2024-03-31 | $1,447,754 | 9,152 | Shares | Sole | 2024-05-14 | |
| No filing history on record for this holder in this stock. | ||||||